Tucked away inside Novartis' fourth-quarter results update this morning is the news that the company has pulled the plug on a drug candidate for Huntington's disease after
Biogen will have to make the case for its amyotrophic lateral sclerosis (ALS) therapy tofersen to an FDA advisory committee in March before it gets a decision on approval.
